Nesiritide of no benefit in acute CHF

Nesiritide in recombinant BNP (that promotes vasodilation) which was FDA approved for use in acute decompensated CHF. However, a large randomized trial, there were no differences in several outcomes in nesiritide compared to placebo (including patient dyspnea scores, 30 day mortality, or 30 day readmission rates), but nesiritide patients were more likely to experience hypotension. Nesiritide cannot be recommended for use in acute CHF (abstract)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment